Should oral prednisone be given to an infant with acute bronchospasm?

Do Not Give Oral Prednisone to Infants with Acute Bronchospasm

Corticosteroid medications should not be used routinely in the management of bronchiolitis in infants 1. This is a firm, evidence-based recommendation from the American Academy of Pediatrics clinical practice guideline.

The Evidence Against Corticosteroids in Infant Bronchospasm

The AAP guideline reviewed systematic reviews and meta-analyses of randomized controlled trials involving nearly 1,200 children with viral bronchiolitis. The findings were clear:

• No benefit in length of hospital stay - pooled analysis showed a statistically insignificant decrease of only 0.38 days 1
• No improvement in clinical scores when compared to placebo 1
• No difference in hospital admission rates following initial emergency department visits 1
• No differences in respiratory rate, oxygen saturation, or hospital revisit rates 1

The evidence quality is rated as Level B (randomized clinical trials with limitations), with a preponderance of harm over benefit 1.

Critical Distinction: Bronchiolitis vs. Asthma

This is where clinical judgment becomes essential. The question uses the term "acute bronchospasm" which requires clarification:

If this is viral bronchiolitis (most common in infants <2 years, characterized by rhinitis, wheezing, crackles, respiratory distress following viral URI):

• Do not use corticosteroids 1
• Up to 60% of hospitalized infants receive steroids inappropriately 1

If this is true asthma exacerbation (less common in infants, but possible):

• The evidence shifts - one study showed oral prednisolone (2 mg/kg/day for 3 days) reduced hospital length of stay and symptom duration in children 6-35 months with virally-induced respiratory distress 2
• However, this study population likely included older infants with reactive airway disease, not classic bronchiolitis

The Clinical Algorithm

1. Age <12 months with first wheezing episode → Almost certainly bronchiolitis → No corticosteroids 1

2. Age 6-24 months with recurrent wheezing and clear asthma phenotype → Consider trial of corticosteroids, but evidence is mixed in this age group 2

3. Supportive care remains the mainstay: assess hydration, supplemental oxygen if SpO2 <90%, monitor respiratory status 1

Common Pitfalls to Avoid

• Don't reflexively prescribe steroids for any infant who wheezes - this is the most common error, occurring in up to 60% of cases 1
• Don't confuse bronchiolitis with asthma - bronchiolitis is a clinical diagnosis based on age, seasonality (RSV peaks December-March), and presentation 1
• Don't use inhaled corticosteroids either - the two available studies showed no benefit in acute bronchiolitis, and safety of high-dose inhaled steroids in infants remains unclear 1

When Steroids Might Be Considered (Rare Exceptions)

The only scenario where corticosteroids have shown benefit in young children with respiratory distress is in those 6-35 months old with documented recurrent wheezing or established asthma 2. Even then, the benefit in true infants (<12 months) remains unproven.

The bottom line: For typical infant bronchiolitis presenting as acute bronchospasm, corticosteroids provide no benefit and expose the child to unnecessary medication risks 1.